Table 1 Characteristics of 838 patients who survived at least one year after esophagectomy for esophageal cancer, stratified by use of aspirin and statins during the first postoperative year

Total

673 (100.0)

165 (100.0)

651 (100.0)

187 (100.0)

Total years of follow-up

1829 (100.0)

458 (100.0)

1758 (100.0)

530 (100.0)

Mean age (standard deviation)

64.0 (9.5)

67.9 (7.1)

63.9 (9.4)

67.7 (7.8)

Sex

 Men

509 (75.6)

148 (89.7)

492 (75.6)

165 (88.2)

 Women

164 (24.4)

17 (10.3)

159 (24.4)

22 (11.8)

Years of education

 ≤ 9

223 (33.1)

62 (37.6)

212 (32.6)

73 (39.0)

 10–12

298 (44.3)

72 (43.6)

292 (44.8)

78 (41.7)

 ≥ 13

149 (22.1)

31 (18.8)

144 (22.1)

36 (19.3)

 Missing

3 (0.5)

0 (0.0)

3 (0.5)

0 (0.0)

Calendar period

 < 2012

283 (42.1)

80 (48.5)

265 (40.7)

98 (52.4)

 ≥ 2012

390 (57.9)

85 (51.5)

386 (59.3)

89 (47.6)

Charlson comorbidity index

 0

332 (49.3)

32 (19.4)

317 (48.7)

47 (25.1)

 1

219 (32.5)

59 (35.8)

215 (33.0)

63 (33.7)

 ≥ 2

122 (18.1)

74 (44.9)

119 (18.3)

77 (41.2)

Aspirin/statin use

 Yes

84 (12.5)

103 (62.4)

62 (9.5)

103 (55.1)

 No

589 (87.5)

62 (37.6)

589 (90.5)

84 (44.9)

Pathological tumor stage

 0-I

280 (41.6)

66 (40.0)

270 (41.5)

76 (40.6)

 II

143 (21.3)

40 (24.2)

141 (21.6)

42 (22.5)

 III

183 (27.2)

46 (27.9)

171 (26.3)

58 (31.0)

 IV

58 (8.6)

12 (7.3)

60 (9.2)

10 (5.4)

 Missing

9 (1.3)

1 (0.6)

9 (1.4)

1 (0.5)

Tumor histology

 Adenocarcinoma

493 (73.3)

130 (78.8)

469 (72.0)

154 (82.4)

 Squamous cell carcinoma

176 (26.2)

35 (21.2)

178 (27.4)

33 (17.6)

 Missing

4 (0.6)

0 (0.0)

4 (0.6)

0 (0.0)

Neoadjuvant chemo(radio)therapy

 Yes

236 (34.1)

90 (54.6)

433 (66.5)

94 (50.3)

 No

437 (64.9)

75 (45.4)

218 (33.5)

93 (49.7)